BIOXYTRAN INC
For the period ended Dec 31, 2023. Filed Mar 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 22, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BIOXYTRAN, INC. | ||
| Dated: March 22, 2024 | By: | /s/ David Platt |
|---|---|---|
| David Platt | ||
| President and Chief Executive Officer (Principal Executive Officer) | ||
| /s/ Ola Soderquist | ||
| Ola Soderquist | ||
| Chief Financial Officer, Secretary & Treasurer | ||
| (Principal Accounting Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below this twenty-second day of March 2024, by the following persons on behalf of the registrant and in the capacities indicated.
| Signature | Title |
|---|---|
| /s/ David Platt, Ph.D. | Chairman of the Board of Directors |
| David Platt, Ph.D. | |
| /s/ Dale H. Conaway, DVM | Director |
| Dale H. Conaway | |
| /s/ Hana Chen-Walden, MD. | Director |
| Hana Chen-Walden, MD | |
| /s/ Alan M. Hoberman, Ph.D. | Director |
| Alan M. Hoberman | |
| /s/ Anders Utter | Director |
| Anders Utter | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.